Overall survival and extent of surgery in adult versus elderly glioblastoma patients: A population based retrospective study

• Published in: Wiener Klinische Wochenschrift 2011-06, Vol.123 (11-12), p.364-368
• Main Authors: Zachenhofer, Iris, Maier, Roland, Eiter, Helmut, Muxel, Bernhard, Cejna, Manfred, DeVries, Alexander, Roessler, Karl
• Format: Article
• Language: English
• Subjects: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating - administration & dosage; Biopsy; Brain - pathology; Brain - surgery; Brain Neoplasms - mortality; Brain Neoplasms - pathology; Brain Neoplasms - surgery; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine - administration & dosage; Dacarbazine - analogs & derivatives; Endocrinology; Female; Gastroenterology; Glioblastoma - mortality; Glioblastoma - pathology; Glioblastoma - surgery; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Original Article; Pneumology/Respiratory System; Quality of Life; Retrospective Studies; Survival Rate
• ISSN: 0043-5325; 1613-7671
• DOI: 10.1007/s00508-011-1577-4

Summary INTRODUCTION: The purpose of this retrospective population based study was to investigate the effect of the extent of surgery on overall survival in young versus adult glioblastoma patients in Vorarlberg/Austria during the last 4 years. METHODS: Forty-eight patients (median age 62.5 years, ranging from 25–82 years, 19 female and 29 male) with histologically proven glioblastoma received surgery (16 biopsies, 18 partial and 14 complete resections) and postoperative chemo-irradiation with concomitant and adjuvant temozolomide. The median follow up of the patient population was 11.7 months (ranging from 3 to 36 months). Postoperative temporary morbidity was found in 5 out of 48 (10.4%) patients, and no mortality or permanent morbidity occurred. One infection led to revision surgery. FINDINGS: Altogether, the 12/24 months overall survival was 54/20.2% with a median survival of 13.7 months. In younger patients (65 yrs, median 73 yrs, 20 patients) the 12/24 months overall survival was 28.8/5.8%, with 7.7 months median survival (Log-rank, p = 0.0005). Extent of surgery influenced overall survival of the adult group nearly significantly (biopsy versus complete resection: p = 0.06), but did not affect overall survival of the elderly ( p = 0.5). CONCLUSIONS: Overall survival of elderly glioblastoma patients treated with surgery and chemo-irradiation with concomitant and adjuvant temozolomide is significantly reduced compared to the younger patients. In addition, in the elderly the extent of surgery did not influence the prognosis in our population.